Abstract 1590
Background
Metastatic renal-cell carcinoma (mRCC) treatment relies on anti-angiogenic therapies. Bone metastases occur in nearly 30% of mRCC and can induce symptomatic skeletal-events (SSE) such as pain requiring radiotherapy, pathologic fractures, and spinal cord compression. SSE can be prevented using bone-targeted agents, e.g. bisphosphonates or denosumab. Data about denosumab and anti-angiogenic combination are scarce.
Methods
This multicenter retrospective study led by GETUG included mRCC patients (pts) who received anti-angiogenic therapies associated with denosumab from January 2013 to December 2015. The primary endpoint was toxicity related to denosumab, especially osteonecrosis of the jaw (ONJ) and hypocalcaemia.
Results
37 pts were identified and 36 analyzed. The mean age was 60.9 year-old (range 42-81). Twenty-four pts (68%) had an odontological consultation before denosumab introduction and 20 pts (58.3%) had a dental panoramic radiography. Five pts (13.9%) developed an ONJ, among them 3 had a dental extraction while on denosumab treatment. Only one out of the 5 pts has completely recovered from his ONJ. No grade 3-4 hypocalcaemia was reported. SSE occurred in 22 pts (61.1%) including bone pain requiring radiation, clinical fractures, and spinal compression in 22, 3, and 2 pts, respectively.
Conclusions
In this real life population, the incidence of SSE was very high in mRCC pts with bone metastases. The combination of denosumab with anti-angiogenic drugs was associated with a high incidence of ONJ that may have been favored by dental extraction while on treatment. The present study underlines the need to improve strategies to prevent the onset of SSE in this population of pts.
Clinical trial identification
Legal entity responsible for the study
N/A
Funding
GETUG
Disclosure
A. Guillot: board PFIZER. S. Negrier: honoraria from Pfizer, Novartis et BMS. D. Pouessel: Board: roche, astellas, Lilly, Novartis, Sanofi Advisory: MSD, AstraZeneca. Speaker : Astellas, Janssen, Boehringer-ingelheim, Sanofi. C. Chevreau: board advisory: Pharmamar Inc, Novartis Inc. L. Albiges: consultaant or advisory role: novartis, pfizer, amgen, BMS, Bayer, Sanofi, Cerulean. K. Fizazi: consultant/advisor for Amgen Inc.,Novartis,Clovis, Pfizer, CSL, Behring, and Bayer- GlaxoSmithKline, and Genentech- speakers' bureau for Genomic Health research funding from Amgen Inc., Novartis, Bayer, and Puma. All other authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract